{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T23:14:57Z","timestamp":1794870897020,"version":"4.9.1"},"reference-count":35,"publisher":"Informa UK Limited","issue":"25","license":[{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Daiichi Sankyo, Inc"},{"name":"Merck & Co., Inc"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncology"],"published-print":{"date-parts":[[2025,10,21]]},"DOI":"10.1080\/14796694.2025.2565995","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T11:26:13Z","timestamp":1759836373000},"page":"3275-3282","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":17,"title":["IDeate-Lung02: a Phase 3 study of second-line ifinatamab deruxtecan in patients with relapsed small cell lung cancer"],"prefix":"10.1080","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7724-7728","authenticated-orcid":false,"given":"Taofeek K.","family":"Owonikoko","sequence":"first","affiliation":[{"name":"University of Maryland","place":["Baltimore, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0780-2677","authenticated-orcid":false,"given":"Lauren","family":"Byers","sequence":"additional","affiliation":[{"name":"University of Texas MD Anderson Cancer Center","place":["Houston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9908-597X","authenticated-orcid":false,"given":"Ying","family":"Cheng","sequence":"additional","affiliation":[{"name":"Jilin Cancer Hospital","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8787-5587","authenticated-orcid":false,"given":"Hidetoshi","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Kindai University","place":["Osaka, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Paz-Ares","sequence":"additional","affiliation":[{"name":"Hospital Universitario 12 de Octubre","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7543-7050","authenticated-orcid":false,"given":"Maurice","family":"P\u00e9rol","sequence":"additional","affiliation":[{"name":"L\u00e9on B\u00e9rard Cancer Center","place":["Lyon, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3436-290X","authenticated-orcid":false,"given":"Haichuan","family":"Hu","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc","place":["Rahway, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Qian","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo, Inc","place":["Basking Ridge, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilio Roi","family":"Garcia","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo, Inc","place":["Basking Ridge, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliette","family":"Godard","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo, Inc., SAS","place":["Paris, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Tang","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo, Inc","place":["Basking Ridge, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5204-3465","authenticated-orcid":false,"given":"Charles M.","family":"Rudin","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center","place":["New York, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,10,7]]},"reference":[{"key":"e_1_3_7_3_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834"},{"key":"e_1_3_7_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-00235-0"},{"key":"e_1_3_7_5_1","unstructured":"National Comprehensive Cancer Network\u00ae. NCCN guidelines: small cell lung cancer version 4. 2025 [cited 2025 Feb 14]. Available from: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1462"},{"key":"e_1_3_7_6_1","unstructured":"National Cancer Institute. Surveillance epidemiology and end results (SEER) cancer statistics explorer network. [cited 2025 Apr 2]. Available from: https:\/\/seer.cancer.gov\/statistics-network\/explorer\/"},{"key":"e_1_3_7_7_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01074"},{"key":"e_1_3_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.03.207"},{"key":"e_1_3_7_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-052556"},{"key":"e_1_3_7_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4978"},{"key":"e_1_3_7_11_1","unstructured":"Japan Lung Cancer Society. Lung cancer treatment guidelines 2024 edition. 2024 [cited 2025 Apr 2]. Available from: https:\/\/www.haigan.gr.jp\/publication\/guideline\/examination\/2024\/"},{"key":"e_1_3_7_12_1","unstructured":"Sandoz Pharmaceuticals d.d. Hycamtin (topotecan) [summary of product characteristics]. Ljubljana Slovenia; 2023 [cited 2025 Feb 14]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/hycamtin-epar-product-information_en.pdf"},{"key":"e_1_3_7_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.5392"},{"key":"e_1_3_7_14_1","unstructured":"PharmaMar SA. Zepzelca\u00ae (lurbinectedin) [prescribing information]. Palo Alto (CA); 2023 [cited 2025 Feb 14]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/213702s008lbl.pdf"},{"key":"e_1_3_7_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.3998"},{"key":"e_1_3_7_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.5821"},{"key":"e_1_3_7_17_1","doi-asserted-by":"publisher","DOI":"10.1177\/17588359211020529"},{"key":"e_1_3_7_18_1","unstructured":"Amgen. Imdelltra\u2122 (tarlatamab-dlle) [prescribing information]. Thousand Oaks (CA); 2024 [cited 2025 Feb 11]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761344s000lbl.pdf"},{"key":"e_1_3_7_19_1","unstructured":"Amgen. Amgen receives manufacturing and marketing approval in Japan for Imdetra\u00ae for the treatment of small cell lung cancer that has progressed after chemotherapy. 2024 [cited 2025 Feb 7]. Available from: https:\/\/www-amgen-co-jp.translate.goog\/media\/press-releases\/2024\/12\/20241227?_x_tr_sl=ja&_x_tr_tl=en&_x_tr_hl=ja&_x_tr_pto=wapp"},{"key":"e_1_3_7_20_1","unstructured":"Amgen. Imdylltra\u2122 (tarlatamab-dlle) [summary of product characteristics]. Cambridge UK; 2024 [cited 2025 Feb 11]. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/100374\/smpc#gref"},{"key":"e_1_3_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.09.057"},{"key":"e_1_3_7_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01751-9"},{"key":"e_1_3_7_23_1","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.41105"},{"key":"e_1_3_7_24_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00264"},{"key":"e_1_3_7_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.8088"},{"key":"e_1_3_7_26_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.600238"},{"key":"e_1_3_7_27_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-21-0554"},{"key":"e_1_3_7_28_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2023-4891"},{"key":"e_1_3_7_29_1","doi-asserted-by":"publisher","DOI":"10.1248\/cpb.c18-00744"},{"key":"e_1_3_7_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12966"},{"key":"e_1_3_7_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.1876"},{"key":"e_1_3_7_32_1","volume-title":"Oral presentation at: 2023 World Conference on Lung Cancer; 2023 Sep 9\u201312","author":"Johnson M","unstructured":"Johnson M, Awad M, Koyama T, et al. Ifinatamab deruxtecan (I-DXd; DS-7300) in patients with refractory SCLC: a subgroup analysis of a phase 1\/2 study. Oral presentation at: 2023 World Conference on Lung Cancer; 2023 Sep 9\u201312; Singapore: Oral presentation 3258."},{"key":"e_1_3_7_33_1","volume-title":"Oral presentation at: 2024 World Conference on Lung Cancer","author":"Rudin CM","unstructured":"Rudin CM, Ahn MJ, Johnson M, et al. Ifinatamab deruxtecan (I-DXd) in extensive-stage small cell lung cancer (ES-SCLC): interim analysis of IDeate-Lung01. Oral presentation at: 2024 World Conference on Lung Cancer; 2024 Sep 7\u201310; San Diego, CA, USA: Oral presentation OA0403."},{"key":"e_1_3_7_34_1","volume-title":"Poster presented at: ESMO Congress","author":"Johnson ML","unstructured":"Johnson ML, Rocha P, Kim YJ, et al. Intracranial response in patients with baseline brain metastases and extensive-stage small cell lung cancer treated with ifinatamab deruxtecan (I DXd) in the IDeate-Lung01 study. Poster presented at: ESMO Congress; 2024 Sep 13\u201317; Barcelona, Spain: Poster 1787P."},{"key":"e_1_3_7_35_1","volume-title":"Poster presented at: World Conference on Lung Cancer","author":"Midde NM","unstructured":"Midde NM, Hennig S, Tran BP, et al. Exposure-response analyses to support ph3 dose selection for I-DXd (ifinatamab deruxtecan) in extensive stage SCLC patients. Poster presented at: World Conference on Lung Cancer; 2024 Sep 7\u201310; San Diego, CA, USA: Poster PT011306."},{"key":"e_1_3_7_36_1","unstructured":"ClinicalTrials.gov. A study of ifinatamab deruxtecan versus treatment of physician\u2019s choice in subjects with relapsed small cell lung cancer (IDeate-Lung02). 2024 [cited 2025 Aug 13]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06203210"},{"key":"e_1_3_7_37_1","unstructured":"Daiichi Sankyo Inc. Data on file. DS7300 - 188 Clinical Study Protocol. Version 3.0. 2024."}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14796694.2025.2565995","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T14:49:26Z","timestamp":1764168566000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14796694.2025.2565995"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,7]]},"references-count":35,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2025,10,21]]}},"alternative-id":["10.1080\/14796694.2025.2565995"],"URL":"https:\/\/doi.org\/10.1080\/14796694.2025.2565995","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,7]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-04-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}